how long have glp-1 been on the market Landscape Of Receptor Agonists In Diabetes And Obesity Treatment GLP-1 Agonists Market Report 2025-2033,

This is the fuller picture of why some people feel depleted on GLP-1 medications

The observed divergence in mortality results when comparing injectable semaglutide to sitagliptin (a placebo proxy) in benchmarking analyses led us to view the results for outcomes containing mortality with skepticism and focused our interpretation on the nonmortality clinical endpoints

Weight loss results with Ozempic can vary

GLP-1s Offer New Hope When Treatment Options Are Limited A growing share of providers are prescribing GLP1 therapies to manage multiple conditions, a trend particularly evident in comorbidities where few therapeutic options exist